Stockscreener 앱 받기
2.07
5.91%
-0.13
전일 마감가:
$2.20
열려 있는:
$2.18
하루 거래량:
57,415
Relative Volume:
0.21
시가총액:
$20.22M
수익:
-
순이익/손실:
$-31.88M
주가수익비율:
-2.76
EPS:
-0.75
순현금흐름:
$-25.20M
1주 성능:
-12.29%
1개월 성능:
-7.17%
6개월 성능:
-15.16%
1년 성능:
-74.19%
1일 변동 폭
$2.05
$2.255
1주일 범위
$2.05
$2.54
52주 변동 폭
$1.17
$12.53
인에잇바이오 Stock (INAB) Company Profile
명칭
In 8 Bio Inc
전화
(646) 600-6438
주소
EMPIRE STATE BUILDING, NEW YORK
INAB을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
2.07 | 21.49M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.17 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.25 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
864.42 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
354.75 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.16 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
인에잇바이오 Stock (INAB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-03-18 | 개시 | Laidlaw | Buy |
| 2022-08-30 | 개시 | H.C. Wainwright | Buy |
인에잇바이오 주식(INAB)의 최신 뉴스
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives - TradingView
Alzheimer’s trial signal and rare skin disease cell therapy at INmune Bio - Stock Titan
Korro Bio, Inc. Unveils KRRO-121 as a Potential First-in-Class Treatment - TradingView
GRI Bio Secures New U.S. Composition of Matter Patent Covering Novel Compound Structures - GlobeNewswire
BofA Securities initiates coverage on Belite Bio stock with Buy rating - Investing.com
Climb Bio, Inc. (NASDAQ:CLYM) Shares Could Be 45% Below Their Intrinsic Value Estimate - Yahoo Finance
CEO shake-up at Zura Bio (NASDAQ: ZURA) with new director added - Stock Titan
KALA Bio Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nuvation Bio Inc. (NYSE:NUVB) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
KALA Stock Price, Forecast & Analysis | KALA BIO INC (NASDAQ:KALA) - Chartmill
With 63% institutional ownership, Gossamer Bio, Inc. (NASDAQ:GOSS) is a favorite amongst the big guns - Yahoo Finance UK
GRI Bio (NASDAQ: GRI) plans 1-for-28 reverse stock split in January - Stock Titan
GRI Bio slashes share count with 1-for-28 split to meet Nasdaq price rule - Stock Titan
Nuvation Bio Inc. (NUVB) Price Target Lowered as IBTROZI Sales Meet Expectations - Insider Monkey
Here’s What the Wall Street Thinks About Nuvation Bio Inc. (NUVB) - Insider Monkey
Access Bio Inc To Acquire 57 Billion Won Worth Of Shares And Majority Stake In Rfbio Co Ltd - TradingView
Palisade Bio Announces Two Abstracts Selected for Poster - GlobeNewswire
GRI Bio (NASDAQ: GRI) approves reverse split to support Nasdaq equity - Stock Titan
Layoff Tracker: Lyra Shutters, EMD Serono Downsizes - BioSpace
Nuvation Bio Signs License and Collaboration Agreement With Eisai - TradingView — Track All Markets
Cabaletta Bio, Inc. Announces 2026 Strategic Priorities - TradingView — Track All Markets
Zura Bio Ltd Announces Corporate and Clinical Updates for 2026 - TradingView — Track All Markets
GRI Bio, Inc. Increases Share Issuance Limit - TradingView — Track All Markets
Can Boundless Bio Inc. stock double in next 5 yearsPortfolio Return Report & Expert Verified Movement Alerts - Улправда
Is Nuvation Bio Inc. stock safe for conservative investorsMarket Risk Report & Daily Momentum Trading Reports - Улправда
Is Mustang Bio Inc. stock positioned for long term growthQuarterly Trade Review & Growth-Oriented Investment Plans - ulpravda.ru
Mercury Bio Launches MB-TIP™--Revolutionizing Immunotherapy with Intracellular Targeting - WV News
GRI Bio, Inc. Announces Positive Phase 2a Trial Data for GRI-0621 - TradingView — Track All Markets
GRI Bio Announces Additional Positive Data from Phase 2a - GlobeNewswire
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026 - TradingView — Track All Markets
Transpire Bio to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
New drug trials target lupus and kidney disease, with 2026 data ahead - Stock Titan
How currency fluctuations impact Palisade Bio Inc. stockEx-Dividend Date Alerts & Low Entry Cost Investment - Улправда
FibroGen (NASDAQ: FGEN) rebrands as Kyntra Bio with new ticker KYNB - Stock Titan
Instil Bio Terminates License and Collaboration Agreement With ImmuneOnco Biopharmaceuticals - TradingView — Track All Markets
KALA BIO Signs Multiple Material Agreements - TradingView — Track All Markets
How a $2 million payment wiped out $10.6 million in company debt - Stock Titan
Provention Bio Appoints Miguel Sanjuan, Ph.D. as Senior Vice President of Research and Early Development - Quantisnow
Alumis Inc. Issues Notice of Material Breach to Climb Bio - TradingView — Track All Markets
Nuvation Bio stock today: NUVB slides nearly 7% as early gains fade - ts2.tech
The economy: Top biopharma trends of 2025 - BioWorld MedTech
Intelligent Bio Solutions Inc Announces New Manufacturing Partnership - TradingView — Track All Markets
Climb Bio, Inc. Files Legal Complaint Over Asset Purchase Agreement - TradingView — Track All Markets
New gut-targeted drug gains key patent in Japan for severe bowel disease - Stock Titan
Biotech shrinks share count 16 to 1—what changes for its shareholders - Stock Titan
10 Stocks Lighting Up Market Ahead of Christmas - Insider Monkey
Ginkgo Bioworks (NYSE: DNA) realigns leadership as Shetty refocuses on lab - Stock Titan
Why Did Indaptus Therapeutics Surge 64% In After-Hours Trading? - Benzinga
Palisade Bio: Gut Prodrug For IBD With Catalysts - Seeking Alpha
What technical signals suggest for GRI Bio Inc. stockEarnings Growth Report & Safe Entry Point Identification - Улправда
Why Cabaletta Bio Inc. stock remains on watchlistsJuly 2025 Institutional & Weekly High Conviction Trade Ideas - Улправда
인에잇바이오 (INAB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.09%
0.48%
자본화:
|
볼륨(24시간):